# PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease

> **NCT00343954** · PHASE1 · UNKNOWN · sponsor: **Angiogenix** · enrollment: 12 (—)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** L-citrulline tablets, 1000 mg

## Key facts

- **NCT ID:** NCT00343954
- **Lead sponsor:** Angiogenix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 12 (—)
- **Last updated:** 2006-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00343954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00343954, "PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00343954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*